<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842084</url>
  </required_header>
  <id_info>
    <org_study_id>20CH237</org_study_id>
    <secondary_id>2021-A00293-38</secondary_id>
    <nct_id>NCT04842084</nct_id>
  </id_info>
  <brief_title>Normal Values of Parameters of Thrombin Generation in Function of Different Tissue Factor Concentrations</brief_title>
  <acronym>NUAGE</acronym>
  <official_title>Determination of Normal Values of Parameters of Thrombin Generation in Fresh PRP and in PPP in Function of Different Tissue Factor Concentrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The thrombin generation assay (TGA) is a good tool for measuring clot formation in plasma.TGA&#xD;
      using Calibrated Automated Thrombography method, enables the quantification of thrombin&#xD;
      concentrations in platelet-rich plasma (PRP) and in platelet-poor plasma (PPP).According to&#xD;
      the clinical context, different TF(Tissue Factor) concentrations (1, 5 and 10 pM) can be used&#xD;
      to trigger the coagulation cascade.The aim of the study is to determine the normal values of&#xD;
      TG (Thrombin Generation) in fresh PRP and in PPP with different TF concentrations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The thrombin generation assay (TGA) is a good tool for measuring clot formation in plasma.&#xD;
      TGA using Calibrated Automated Thrombography method, enables the quantification of thrombin&#xD;
      concentrations in platelet-rich plasma (PRP) and in platelet-poor plasma (PPP). The thrombin&#xD;
      generation (TG) profile varies from patient to patient and depends on the activity of the pro&#xD;
      and anti-coagulant factors. The TGA values depend on the analytical conditions such as Tissue&#xD;
      Factor (TF) concentration and the plasma analyzed (PRP or PPP). According to the clinical&#xD;
      context, different TF concentrations (1, 5 and 10 pM) can be used to trigger the coagulation&#xD;
      cascade.&#xD;
&#xD;
      As a consequence, the reference values vary with the analytical conditions but also with the&#xD;
      studied population (men or women). The reference values are not provided by the manufacturer&#xD;
      and each laboratory has to establish the normal values according to the analytical conditions&#xD;
      chosen for the pathology explored (hemorrhagic or thrombotic). Moreover, in PPP, the TG&#xD;
      results can be different according to batch reagents. That is the reason why plasma will be&#xD;
      frozen for a new determination in case of deviation of the result of the control plasma.&#xD;
&#xD;
      The aim of the study is to determine the normal values of TG in fresh PRP and in PPP with&#xD;
      different TF concentrations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombin generation parameter in PRP (Peak : nmol thrombin)</measure>
    <time_frame>At inclusion</time_frame>
    <description>Peak measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombin generation parameter in PRP (ETP : nmol*min)</measure>
    <time_frame>At inclusion</time_frame>
    <description>Endogenous Thrombin Potential measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombin generation parameter in PRP (LT : min)</measure>
    <time_frame>At inclusion</time_frame>
    <description>Lag Time measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombin generation parameter in PRP (V : nmol/min)</measure>
    <time_frame>At inclusion</time_frame>
    <description>Velocity index measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombin generation parameter in PRP (TTP : min)</measure>
    <time_frame>At inclusion</time_frame>
    <description>Time to Peak measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombin generation parameter in PRP (ST : min)</measure>
    <time_frame>At inclusion</time_frame>
    <description>Start Tail measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation parameters in PPP (Peak : nmol thrombin)</measure>
    <time_frame>At inclusion</time_frame>
    <description>Peak measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation parameters in PPP (ETP : nmol*min)</measure>
    <time_frame>At inclusion</time_frame>
    <description>Endogenous Thrombin Potential measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation parameters in PPP (LT: min)</measure>
    <time_frame>At inclusion</time_frame>
    <description>Lag Time measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation parameters in PPP (V : nmol/min)</measure>
    <time_frame>At inclusion</time_frame>
    <description>Velocity index measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation parameters in PPP (TTP : min)</measure>
    <time_frame>At inclusion</time_frame>
    <description>Time to Peak measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation parameters in PPP (ST: min)</measure>
    <time_frame>At inclusion</time_frame>
    <description>Start Tail measurement</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <description>Healthy volunteers both sex aged between 18 and 50 without personal or family history of hemorrhage, thrombosis before 45 years old,</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>sampling of 10 S-Monovette tubes (Sarstedt) 4.3 ml of blood specifically for the study representing a total blood volume of 43 ml</description>
    <arm_group_label>healthy volunteers</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers both sex aged between 18 and 50 without personal or family history of&#xD;
        hemorrhage, thrombosis before 45 years old,&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient beneficiary or affiliated to Social security system&#xD;
&#xD;
          -  Consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Personal or family history (parents, brothers, sisters) of hemorrhage&#xD;
&#xD;
          -  Personal or family history (parents, brothers, sisters) of thrombosis before 45 years&#xD;
             old&#xD;
&#xD;
          -  Taking an anti-inflammatory or an aspirin one week before the sampling&#xD;
&#xD;
          -  Current take of an anticoagulant or antiaggregant treatment&#xD;
&#xD;
          -  Surgery within previous month before the sampling&#xD;
&#xD;
          -  Chronic pathology responsible of an inflammatory syndrome&#xD;
&#xD;
          -  Episode of viral or bacterial infections&#xD;
&#xD;
          -  Known HIV or Hepatitis C Virus (HCV) infection&#xD;
&#xD;
          -  Participation in a therapeutic clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte Tardy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brigitte Tardy, MD</last_name>
    <phone>(0)477828591</phone>
    <phone_ext>+33</phone_ext>
    <email>brigitte.tardy@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurelie Montmartin</last_name>
    <phone>(0)4 77 42 14 00</phone>
    <phone_ext>+33</phone_ext>
    <email>aurelie.montmartin@univ-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Saint-Etienne - Service d'HÃ©matologie</name>
      <address>
        <city>Saint-Ãtienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brigitte TARDY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blood</keyword>
  <keyword>plasma</keyword>
  <keyword>blood platelets</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

